secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001937653-25-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports $122.7M net loss for 2024; Ziihera approval drives $25M milestone
--------------------------------------------------------------------------------

- Revenue $76.3M in 2024 (vs $76.0M in 2023); net loss $122.7M vs $118.7M loss prior year.
- Cash resources $324.2M at Dec 31, 2024; projected runway into 2H-2027 with anticipated regulatory milestones.
- Ziihera (zanidatamab) FDA approved for HER2+ BTC in Nov 2024; initial net sales $1.1M; $25M milestone earned from Jazz.
- Phase 1 studies initiated for ZW191 and ZW171; IND for ZW251 accelerated to mid-2025; ZW220 preparations paused.
- Non-cash impairment charge of $17.3M for discontinuation of zanidatamab zovodotin; $14M milestone from GSK in Jan 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000012/0001937653-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000012/zyme-20250305.htm
  HTML page:      https://secwatch.observer/filing/0001937653-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer